Circulating chemerin level and the risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis

Rastkar, Mohsen; Nikniaz, Leila; Farhangi, Mahdieh Abbasalizad; Nikniaz, Zeinab

doi:10.1007/s40200-023-01187-4

Cited by 2 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other inflammatory markers such as chemerin, ferritin, M65, and LECT2 decreased, while adiponectin increased after the dietary intervention in our study, suggesting a potential role of dietary modifications in modulating systemic inflammation. Chemerin and RBP4 are associated with obesity and metabolic syndrome markers such as BMI, body fat, leptin, lipid profile, blood glucose measurements, and fatty liver [ 52 , 53 , 54 ]. Similarly, LECT2 mediates obesity-related metabolic disturbances, and its downregulation ameliorates hepatic steatosis [ 55 ].…”

Section: Discussionmentioning

confidence: 99%

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

Tobaruela-Resola,

Riezu-Boj,

Milagro

et al. 2024

Nutrients

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD), with a prevalence of 30% of adults globally, is considered a multifactorial disease. There is a lack of effective non-invasive methods for accurate diagnosis and monitoring. Therefore, this study aimed to explore associations between changes in circulating miRNA levels, inflammatory markers, and depressive symptoms with hepatic variables in MASLD subjects and their combined potential to predict the disease after following a dietary intervention. Biochemical markers, body composition, circulating miRNAs and hepatic and psychological status of 55 subjects with MASLD with obesity and overweight from the FLiO study were evaluated by undergoing a 6-, 12- and 24-month nutritional intervention. The highest accuracy values of combined panels to predict the disease were identified after 24 months. A combination panel that included changes in liver stiffness, high-density lipoprotein cholesterol (HDL-c), body mass index (BMI), depressive symptoms, and triglycerides (TG) yielded an AUC of 0.90. Another panel that included changes in hepatic fat content, total cholesterol (TC), miR15b-3p, TG, and depressive symptoms revealed an AUC of 0.89. These findings identify non-invasive biomarker panels including circulating miRNAs, inflammatory markers, depressive symptoms and other metabolic variables for predicting MASLD presence and emphasize the importance of precision nutrition in MASLD management and the sustained adherence to healthy lifestyle patterns.

show abstract

Section: Discussionmentioning

confidence: 99%

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

Tobaruela-Resola,

Riezu-Boj,

Milagro

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

“…However, some other investigations suggested that the use of antihypertensive medications has a protective effect on acute lung injury. 12 In terms of diabetes, earlier studies showed that the severity and odds of mortality are significantly higher in patients with poorly controlled glycemia compared to people with well-controlled glycemia. However, the results of studies regarding the effect of anti-diabetic agents 13 and respiratory medication 14 on COVID-19 outcomes were inconclusive.…”

Section: Introductionmentioning

confidence: 99%

Association of Cardiovascular Disease, Respiratory Diseases, and Diabetes Treatment With COVID-19 Mortality in Hospitalized Patients

Nikniaz,

Faghih Dinevari,

Mokhtari

2023

Int J Drug Res Clin

View full text Add to dashboard Cite

Background: The prevalence of the coronavirus disease 2019 (COVID-19) in patients with preexisting non-communicable disease was high, and there was a question regarding the effect of the usage of medications on COVID-19 outcomes in these patients. Therefore, this study investigated the outcome of patients with different cardiovascular diseases (CVDs), respiratory diseases, and diabetes drug use. Methods: In this analytical longitudinal study, information was collected on clinical laboratory data, COVID-19 severity, comorbidities, and drug use. The follow-up time was from enrollment to discharge or death. Results: A total of 1046 hospitalized patients with COVID-19 participated in this analytical longitudinal study. The most commonly used drugs were CVD drugs (39.4%) and diabetes drugs (19.7%). The frequency of drug use was statistically similar between survivors and non-survivors except for diabetic drug use which was significantly higher in non-survivors (P=0.04). Patients who used the diabetic drugs were more likely to die (odds ratio [OR]: 1.41, 95% CI: 1.008-1.97). Moreover, the association was not significant after adjusting to confounding factors, and there was no significant association between other drug use and death in patients with COVID-19. Conclusion: The result of the present study showed that antihypertensive treatments, antidiabetic, and respiratory disease drugs were not associated with higher deaths in hospitalized patients with COVID-19.

show abstract

Circulating chemerin level and the risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis

Cited by 2 publications

References 40 publications

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

Association of Cardiovascular Disease, Respiratory Diseases, and Diabetes Treatment With COVID-19 Mortality in Hospitalized Patients

Contact Info

Product

Resources

About